Yeztugo Kit
Product Images NDC 61958-3402

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Yeztugo (NDC 61958-3402). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Gilead Sciences, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Yeztugo 01)

This text indicates the availability of components for single-use, including syringes with withdrawal and injection needles of specific sizes: 18G, 1% inch and 226, %h inch. The mention of "2 x2 x2" may refer to the quantity or stock number.*

FDA Label Image

Figure 2 (Yeztugo 02)

This text provides instructions for preparing vial and syringe for injection. It includes details on using a 22G injection needle, expelling air bubbles, selecting and cleaning an injection site, administering subcutaneously, and repeating the steps for a second injection. Additionally, it highlights the importance of ensuring the withdrawal needle is correctly attached, the solution in the syringe is clear with no particles, and the product is not expired. The recommended injection sites are at least 2 inches from the navel, with a 50° angle preferred.*

FDA Label Image

Chemical Structure (Yeztugo 03)

FDA Label Image

Principal Display Panel (4 Tablet Bottle Label)

This text provides information about Yeztugo tablets, each containing 300 mg of lenacapavir sodium. The tablets should be stored between 20°C-25°C (68°F-77°F) with excursions permitted between 15°C-30°C (59°F-86°F). The recommended dosage should be discussed with a healthcare provider, and the tablets should only be dispensed in their original container. It is important to keep the tablets out of reach of children. The tablets are manufactured for Gilead Sciences, Inc., and the healthcare provider will provide guidance on when to take the tablets.*

FDA Label Image

Principal Display Panel (Kit Carton)

This is a description of Yeztugo (lenacapavir) injection, with a concentration of 463.5 mg/1.5 mL. The packaging contains 2x 1.5 mL lenacapavir single-dose vials, 2 withdrawal needles (18 gauge, 1% inch), 2 syringes, and 2 injection needles (22 gauge, % inch). To receive the full 927 mg dose, both vials must be administered. The product is for subcutaneous injection and is for administration by healthcare professionals only. The package also includes prescribing information, instructions for use, and patient information. Developed by GILEAD.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.